Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations

Human Molecular Genetics

Volumn 24, Issue 4, 2015, Pages 926-938

  Osborn, Alexander J ^a   Dickie, Peter ^a   Neilson, Derek E ^a   Glaser, Kathryn ^a   Lynch, Kaari A ^a   Gupta, Anita ^a   Dickie, Belinda Hsi ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; CD31 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYCLOOXYGENASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PODOPLANIN; PROTEIN KINASE B; RAPAMYCIN; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; NAPHTHYRIDINE DERIVATIVE; PIK3CA PROTEIN, HUMAN; SAR131675;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CELL ISOLATION; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CLOVES SYNDROME; CONTROLLED STUDY; DNA SEQUENCE; ENDOTHELIUM CELL; FEMALE; GENE; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; LYMPHATIC ENDOTHELIAL CELL; LYMPHATIC MALFORMATION; MALE; PIK3CA GENE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOMATIC MUTATION; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; LYMPHATIC ABNORMALITIES; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHENOTYPE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ADOLESCENT; ALLELES; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC ABNORMALITIES; MALE; MUTATION; NAPHTHYRIDINES; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; YOUNG ADULT;

EID: 84922469410     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu505     Document Type: Article

References (43)

1. Uebelhoer, M., Boon, L.M. and Vikkula, M. (2012) Vascular anomalies: from genetics toward models for therapeutic trials. Cold Spring Harb. Perspect. Med., 2, a006239.
2. Cahill, A.M. and Nijs, E.L. (2011) Pediatric vascular malformations: pathophysiology, diagnosis, and the role of interventional radiology. Cardiovasc. Interv. Rad., 34, 691-704.
3. Greene, A.K. (2012) Current concepts of vascular anomalies. J. Craniofac. Surg., 23, 220-224.
4. Shirley, M.D., Tang, H., Gallione, C.J., Baugher, J.D., Frelin, L.P., Cohen, M.D., North, P.E., Marchuk, D.A., Comi, A.N. and Pevsner, J.P. (2013) Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N. Eng. J. Med., 368, 1971-1979.
5. Vikkula, M., Boon, L.M., Carraway III, K.L., Calvert, J.T., Diamonti, A.J., Goumerov, B., Pasyk, K.A., Marchuk, D.A., Warman, M.L., Cantley, L.C. et al. (1996) Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell, 87, 1181-1190.
6. Schulte-Merker, S., Sabine, A. and Petrova, T.V. (2011) Lymphatic vascular morphogenesis in development, physiology, and disease. J. Cell Biol., 193, 607-618.
7. Perkins, J.A., Manning, S.C., Tempero, R.M., Cunningham, M.J., Edmonds, J.L. Jr, Hoffer, F.A. and Egbert, M.A. (2010) Lymphatic malformations: current cellular and clinical investigations. Otolaryng. Head Neck Surg., 142, 789-794.
8. Blatt, J., McLean, T.W., Castellino, S.M. and Burkhart, C.N. (2013) A review of contemporary options for medical management of hemangiomas, other vascular tumors, and vascular malformations. Pharmacol. Therapeut., 139, 327-333.
9. Boardman, K.C. and Swartz, M.A. (2003) Interstitial flow as a guide for lymphangiogenesis. Circ. Res., 92, 801-808.
10. Planas-Paz, L., Strilic, B., Goedecke, A., Breier, G., Fassler, R. and Lammert, E. (2012) Mechanoinduction of lymph vessel expansion. EMBO J., 31, 788-804.
11. Kurek, K.C., Luks, V.L., Ayturk, U.M., Alomari, A.I., Fishman, S.J., Spencer, S.A., Mulliken, J.B., Bowen, M.E., Yamamoto, G.L., Kozakewich, H.P. et al. (2012) Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am. J. Hum. Genet., 90, 1108-1115.
12. Baradaran-Heravi, A. (2012) PIK3CA, a hotspot for post-zygotic mutations in nonhereditary overgrowth syndromes. Clin. Genet., 82, 523-525.
13. Liu, N-F., Lu, Q. and Yan, Z-X. (2010) Lymphatic malformation is a common component of Klippel-Trenaunay syndrome. J. Vasc. Surg., 52, 1557-1563.
14. Cohen, C.M. (2013) Proteus syndrome review: molecular, clinical, and pathologic features. Clin. Genet., 85, 111-119.
15. Lee, B.H., Kim, J.-M., Jin, H.Y., Kim, G-H., Choi, J.-H. and Yoo, H.-W. (2011) Spectrum of mutations in Noonan syndrome and their correlation with phenotypes. J. Pediatr., 159, 1029-1035.
16. Burrows, P.E., Gonzalez-Garay, M.L., Rasmussen, J.C., Aldrich, M.B., Guillod, R., Maus, E.A., Fife, C.E., Kwon, S., Lapinski, P.E., King, P.D. and Sevick-Muraca, E.M. (2013) Lymphatic abnormalities are associated with RASA1 gene mutations in mouse and man. Proc. Natl. Acad. Sci. USA, 110, 8621-8626.
17. Alitalo, K. (2011) The lymphatic vasculature in disease. Nat. Med., 17, 1371-1380.
18. Makinen, T., Veikkola, T., Mustjoki, S., Karpanen, T., Catimel, B., Nice, E.C., Wise, L., Mercer, A., Kowalski, H., Kerjaschki, D. et al. (2001) Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J., 20, 4762-4773.
19. Wigle, J.T., Harvey, N., Detmar, M., Lagutina, I., Grosveld, G., Gunn, M.D., Jackson, D.G. and Oliver, G. (2002) An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J., 21, 1505-1513.
20. Kriehuber, E., Breiteneder-Geleff, S., Groeger, M., Soleiman, A., Schoppmann, S.F., Stingl, G., Kerjaschki, D. and Maurer, D. (2001) Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. J. Exp. Med., 194, 797-808.
21. Kang, S., Bader, A.G. and Vogt, P.K. (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. USA, 102, 802-807.
22. Stambolic, V., Suzuki, A., de la Pompa, J.L., Brothers, G.M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J.M., Siderovski, D.P. and Mak, T.W. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell, 95, 29-39.
23. Mendoza, M.C., Er, E.E. and Blenis, J. (2011) The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci., 36, 320-328.
24. Coso, S., Zeng, Y., Opeskin, K. and Williams, E.D. (2012) Vascular endothelial growth factor receptor-3 directly interacts with phosphatidylinositol 3-kinase to regulate lymphangiogenesis. PLoS ONE, 7, e39558.
25. Thurston, G. and Daly, C. (2012) The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway. Cold Spring Harb. Perspect. Med., 2, a006550.
26. Mouta-Bellum, C., Kirov, A., Miceli-Libby, L., Mancini, M.L., Petrova, T.V., Liaw, L., Prudovsky, I., Thorpe, P.E., Miura, N., Cantley, L.C. et al. (2009) Organ-specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene-targeting of the PI3K regulatory isoforms p85alpha, p55alpha, and p50alpha. Dev. Dynam., 238, 2670-2679.
27. Karpanen, T. and Alitalo, K. (2008) Molecular biology and pathology of lymphangiogenesis. Annu. Rev. Path., 3, 367-397.
28. Zhuo, W., Jia, L., Song, N., Lu, X.A., Ding, Y., Wang, X., Song, X., Fu, Y. and Luo, Y. (2012) The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogenesis. Clin. Cancer Res., 18, 5387-5398.
29. Young, K., Conley, B., Romero, D., Tweedie, E., O'Neill, C., Pinz, I., Brogan, L., Lindner, V., Liaw, L. and Vary, C.P. (2012) BMP9 regulates endoglin-dependent chemokine responses in endothelial cells. Blood, 120, 4263-4273.
30. Karnezis, T., Shayan, R., Fox, S., Achen, M.G. and Stacker, S.A. (2012) The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway. Oncotarget, 3, 890-903.
31. Folkes, A.J., Ahmadi, K., Alderton, W.K., Alix, X., Baker, S.J., Box, G., Chuckowree, I.S., Clarke, P.A., Depledge, P., Eccles, S.A. et al. (2008) The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperizan-1-ylmethyl)-4-morpholin-4-yl-thienol[3, 2-d] pyrimidine (GDC-0941) as a potent, selective, orally available inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem., 51, 5522-5532.
32. Alam, A., Blanc, I., Gueguen-Dorbes, G., Duclos, O., Bonnin, J., Barron, P., Laplace, M.C., Morin, G., Gaujarengues, F., Dol, F. et al. (2012) SAR131675, a potent and selective VEGFR-3-TK inhibitor with antilymphangiogenic, antitumoral, and antimetastatic activities. Mol. Cancer Therapeut., 11, 1637-1649.
33. Bader, A.G., Kang, S., Zhao, L. and Vogt, P.K. (2005) Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer, 5, 921-929.
34. Keppler-Noreuil, K.M., Sapp, J.C., Lindhurst, M.J., Parker, V.E.R., Blumhorst, C., Darling, T., Tosi, L.L., Huson, S.M., Whitehouse, R.W., Jakkula, E. et al. (2014) Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am. J. Med. Genet. A, 9999, 1-21.
35. Boscolo, E., Mulliken, J.B. and Bischoff, J. (2013) Pericytes from infantile hemangioma display proangiogenic properties and dysregulated angiopoietin-1. Arterioscler. Thromb. Vas. Biol., 33, 501-509.
36. Choi, I., Lee, S. and Hong, Y.K. (2012) The new era of the lymphatic system: no longer secondary to the blood vascular system. Cold Spring Harb. Perspect. Med., 2, a006445.
37. Zhou, F., Chang, Z., Zhang, L., Hong, Y.K., Shen, B., Wang, B., Zhang, F., Lu, G., Tvorogov, D., Alitalo, K. et al. (2010) Akt/Protein kinase B is required for lymphatic network formation, remodeling, and valve development. Am. J. Pathol., 177, 2124-2133.
38. Cheng, H.T. and Hung, W.C. (2013) Inhibition of proliferation, sprouting, tube formation and Tie2 signaling of lymphatic endothelial cells by the histone deacetylase inhibitor SAHA. Oncol. Rep., 30, 961-967.
39. Bachelor, M.A., Cooper, S.J., Sikorski, E.T. and Bowden, G.T. (2005) Inhibition of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase decreases UVB-induced activator protein-1 and cyclooxygenase-2 in a SKH-1 hairless mouse model. Mol. Cancer Res., 3, 90-99.
40. Hutti, J.E., Pfefferle, A.D., Russell, S.C., Sircar, M., Perou, C.M. and Baldwin, A.S. (2012) Oncogenic PI3K mutations lead to NF-kappaB-dependent cytokine expression following growth factor deprivation. Cancer Res., 72, 3260-3269.
41. Courtois-Cox, S., Jones, S.L. and Cichowski, K. (2008) Many roads lead to oncogene-induced senescence. Oncogene, 27, 2801-2809.
42. Korff, T. and Augustin, H.G. (1998) Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J. Cell Biol., 143, 1341-1352.
43. Board, R.E., Thelwell, N.J., Ravetto, P.F., Little, S., Ranson, M., Dive, C., Hughes, A. and Whitcombe, D. (2008) Multiplexed assays for detection of mutations in PIK3CA. Clin. Chem., 54, 757-760.